RNA Sequencing analysis revealed the coexistence of mutations in a three-gene signature that can be viewed as a biomarker for diagnosis of endometrioid EC, while the absence of three-gene signature mutations when TP53 was mutated was found to be diagnostic of serous carcinomas (Cuevas et al., 2019). This evidence concerns the gene TP53 and serous adenocarcinoma.